MULTIPLEX DETECTION OF TUMOR MARKERS FOR DIFFERENT STAGES OF COLORECTAL CANCER

 Introduction. Colorectal cancer is one of the most common cancers worldwide. In the Republic of Kazakhstan, over the past decade, the incidence rates of colon and rectal cancers have increased by 23 % and 17 %, respectively. Although colorectal cancer screening rates have increased over time, it is necessary to identify new serum markers for early detection and prognosis of this cancer.

The aim of the study was to evaluate the  diagnostic value of serum biomarkers for colorectal cancer.

Material and Methods. Biomarkers were studied by immunofluorescence method using xMap technology, which included simultaneous immunofluorescence determination on magnetic spheres CA125, CA15–3, CA19–9, CEA, CYFRA21–1, sFAS, sFasL, HE4, Osteopontin, VEGF-A, pd-L1.

Results. The study showed no significant differences in the levels of markers
between healthy subjects (control group) and patients with bowel diseases. In cancer patients, СEA and OpN markers increased with increasing tumor stage, and were significantly higher than those observed in patients with bowel diseases and controls. The CA125 marker was significantly higher in patients with stage IV cancer then in patients with I–III stages.

Conclusion. Our study revealed that the new pd-L1 marker can serve as a significant biomarker for colorectal cancer. 

1. Brody H. Colorectal cancer. Nature. 2015 May 14; 521(7551): S1. doi: 10.1038/521S1a. PMID: 25970450.

2. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1; 136(5): E359–86. doi: 10.1002/ijc.29210.

3. Odintsova I.N., Cheremisina O.V., Pisareva L.F., Spivakova I.O., Vusik M.V. Epidemiology of colorectal cancer in Tomsk region. Siberian Journal of Oncology. 2017; 16(4): 89–95. (in Russian). doi: 10.21294/1814-4861-2017-16-4-89-95.

4. Indicators of the cancer service of the Republic of Kazakhstan for 2017 (statistical materials). KIOR. 2018. 128 р. (in Russian).

5. Dokhdyrbai M., Esentaeva S.E., Toleukhanov T.S., Bismildina G.S., Umbetyarova L.B. Analysis of the incidence of colorectal cancer in the Republic of Kazakhstan in 2009–2013. KazNMU Bulletin. 2016; 1: 704–709. (in Russian).

6. Yotsukura S., Mamitsuka H. Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint. Crit Rev Oncol Hematol. 2015 Feb; 93(2): 103–15. doi: 10.1016/j.critrevonc.2014.10.002.

7. Lou E., Vogel R.I., Teoh D., Hoostal S., Grad A., Gerber M., Monu M., Lukaszewski T., Deshpande J., Linden M.A., Geller M.A. Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer. Lab Med. 2018; 49(2): 134–9. doi: 10.1093/labmed/lmx084.

8. Voith von Voithenberg L., Crocetti E., Martos C., Dimitrova N., Giusti F., Randi G., Rooney R., Dyba T., Bettio M., Negrão Carvalho R. Cancer registries guardians of breast cancer biomarker information: A systematic review. Int J Biol Markers. 2019 Jun; 34(2): 194–199. doi: 10.1177/1724600819836097.

9. Otoshi T., Nagano T., Tachihara M., Nishimura Y. Possible Biomarkers for Cancer Immunotherapy. Cancers (Basel). 2019; 11(7): 935. doi: 10.3390/cancers1107093.

10. George A.P., Kuzel T.M., Zhang Y., Zhang B. The Discovery of Biomarkers in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019 Apr 4; 17: 484–97. doi: 10.1016/j.csbj.2019.03.015.

11. Pellino G., Gallo G., Pallante P., Capasso R., De Stefano A., Maretto I., Malapelle U., Qiu S., Nikolaou S., Barina A., Clerico G., Reginelli A., Giuliani A., Sciaudone G., Kontovounisios C., Brunese L., Trompetto M., Selvaggi F. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterol Res Pract. 2018 Jun 13; 2018: 2397863. doi: 10.1155/2018/2397863.

12. Nikolaou S., Qiu S., Fiorentino F., Rasheed S., Tekkis P., Kontovounisios C. Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctol. 2018 Jul; 22(7): 481–498. doi: 10.1007/s10151-018-1820-3.

13. Tong G., Xu W., Zhang G., Liu J., Zheng Z, Chen Y., Niu P., Xu X. The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer – A retrospective cohort study. Cancer Med. 2018; 7(11): 5327–38. doi: 10.1002/cam4.1814.

14. Huang R.H., Quan Y.J., Chen J.H., Wang T.F., Xu M., Ye M., Yuan H., Zhang C.J., Liu X.J., Min Z.J. Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling Pathway. Cell Physiol Biochem. 2017; 41(5): 1851–1864. doi: 10.1159/000471933.

15. Kamal A., Darwish R.K., Saad S., Salama M., El-Baradie T.S, Mahmoud H.G., Elshiwy Y. Association of Osteopontin Gene Polymorphisms with Colorectal Cancer. Cancer Invest. 2017; 35(2): 71–7. doi: 10.1080/07357907.2016.1247454.

16. Wei R., Wong J.P.C., Kwok H.F. Osteopontin a promising biomarker for cancer therapy. J Cancer. 2017 Jul 15; 8(12): 2173–2183. doi: 10.7150/jca.20480.

17. Peltonen R., Österlund P., Lempinen M., Nordin A., Stenman U.H., Isoniemi H. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases. Tumour Biol. 2018 Jan; 40(1): 1010428317752944. doi: 10.1177/1010428317752944.

18. Yu Z., Chen Z., Wu J., Li Z., Wu Y. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis. PLoS One. 2017; 12(11): e0188139. doi: 10.1371/journal.pone.0188139.

19. Kim N.H., Lee M.Y., Park J.H., Park D.I., Sohn C.I., Choi K., Jung Y.S. Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia. Yonsei Med J. 2017 Sep; 58(5): 918–24. doi: 10.3349/ymj.2017.58.5.918.

20. Liang S., Chang L. Serum matrix metalloproteinase-9 level as a biomarker for colorectal cancer: a diagnostic meta-analysis. Biomark Med. 2018 Apr; 12(4): 393–402. doi: 10.2217/bmm-2017-0206.

21. Thomas D.S., Fourkala E.O., Apostolidou S., Gunu R., Ryan A., Jacobs I., Menon U., Alderton W., Gentry-Maharaj A., Timms J.F. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer. 2015 Jul 14; 113(2): 268–74. doi: 10.1038/bjc.2015.202.

22. Gao Y., Wang J., Zhou Y., Sheng S., Qian S.Y., Huo X. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Sci Rep. 2018 Feb 9; 8(1): 2732. doi: 10.1038/s41598-018-21048-y.

23. Chang S.J., Ge X.S., Xu Z.Y., Qi X.W., Chen X.P. Lower serum CA125 level, negative vascular invasion, and wild BRAF were strongly associated with better 2-year disease-free survival in patients with stage III colorectal cancer who received adjuvant chemotherapy. Cancer Biomark. 2018; 22(1): 161–8. doi: 10.3233/CBM-181179.

24. Huang C.J., Jiang J.K., Chang S.C., Lin J.K., Yang S.H. Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women. Medicine (Baltimore). 2016 Nov; 95(47): e5177. doi: 10.1097/MD.0000000000005177.

25. Kemal Y.N., Demirag G.N., Bedir A.M., Tomak L., Derebey M., Erdem D.L., Gör U., Yücel I. Serum human epididymis protein 4 levels in colorectal cancer patients. Mol Clin Oncol. 2017 Sep; 7(3): 481–485. doi: 10.3892/mco.2017.1332.

26. Cao H., Fang X., Li H., Li H., Kong J. Ultrasensitive detection of mucin 1 biomarker by immuno-loop-mediated isothermal amplification. Talanta. 2017 Mar 1; 164: 588–592. doi: 10.1016/j.talanta.2016.07.018.

27. Attallah A.M., El-Far M., Ibrahim A.R., El-Desouky M.A., Omran M.M., Elbendary M.S., Attallah K.A., Qura E.R., Abdallah S.O. Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1. Br J Biomed Sci. 2018; 75(3): 122–7. doi: 10.1080/09674845.2018.1456309.

28. Goulart A., Ferreira C., Rodrigues A., Coimbra B., Sousa N., Leão P. The correlation between serum vascular endothelial growth factor (VEGF) and tumor VEGF receptor 3 in colorectal cancer. Ann Surg Treat Res. 2019 Jul; 97(1): 15–20. doi: 10.4174/astr.2019.97.1.15.

29. Xu H., Ren Y.J., Liu K., Min X.L., Yang L., Zhou Y., Zheng J., Yang C. Correlations of serum VEGF and MMP-2 levels with CLM in CRC patients and effects of TACE on their expressions. Eur Rev Med Pharmacol Sci. 2018 Jun; 22(11): 3394–3401. doi: 10.26355/eurrev_201806_15161.

30. Karpuz T., Araz M., Korkmaz L., Kılınc I., Findik S., Karaagaç M., Eryilmaz M.K., Artac M. The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer. J Gastrointest Cancer. 2020 Jun; 51(2): 491–497. doi: 10.1007/s12029-019-00263-4.

31. Chen H., Qian J., Werner S., Cuk K., Knebel P., Brenner H. Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer. Clin Epidemiol. 2017; 9: 517–26. doi: 10.2147/CLEP.S144171.

32. Sun C., Mezzadra R., Schumacher T.N. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018; 48(3): 434–52. doi: 10.1016/j.immuni.2018.03.014.